February 15, 2012—Dava Pharmaceuticals has agreed to pay 340B covered entities $185,557 as part of a settlement with the federal government and a whistleblower over charges that it violated the federal False Claims Act by misreporting drug prices in order to reduce its Medicaid drug rebate and 340B drug discount obligations.
According to the Jan. 24 settlement, which the U.S. Justice Department (DOJ) announced on Feb. 8, Dava, which is based in New Jersey, agreed to “use its best efforts to identify affected [340B covered] entities and the amounts they were overcharged for purchases of Dava’s versions of the drugs cefdinir, clarithromycin, methotrexate, and/or rheumatrex.”
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)